Viewing Study NCT02572167

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:33 AM
Ignite Modification Date: 2026-02-20 @ 9:54 PM
Study NCT ID: NCT02572167
Status: COMPLETED
Last Update Posted: 2022-11-08
First Post: 2015-10-07
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Sponsor: Seagen Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Monomethyl auristatin E View
None Antigens, CD30 View
None Antibody-Drug Conjugate View
None Antibodies, Monoclonal View
None Immunotherapy View
None Autologous stem cell transplant View